Compare 10X Genomics Inc (TXG) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Valero Energy Corporation — how do they compare? 10X Genomics Inc trades at $81.37 (market cap $10.07B), while Valero Energy Corporation trades at $434.52 (market cap $127.78B). The key difference: Valero Energy Corporation is far larger — about 12.7× 10X Genomics Inc's market cap, and Valero Energy Corporation pays a 1.08% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 91 Days and Valero Energy Corporation for 56 Days on average.
| TXG | VLO | |
|---|---|---|
Market Cap | $10.07B | $127.78B |
Volume | 5,657,286 | 2,570,225 |
Sector | Health | Energy |
52-Week High | $97.74 | $443.80 |
52-Week Low | $11.48 | $156.39 |
Typical Hold Time | 91 Days | 56 Days |
Enterprise Value | $9.59B | $131.26B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Valero Energy (VLO) trades at $441.93, up 4.2% today, near its 52-week high with strong bullish momentum from moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 expected at $20.17 EPS. Revenue declined to $122.69B in 2025, but net income margin improved to 5.17%, supported by a robust ROE of 29.31%. Analyst consensus is bullish with a $408.10 price target, though RSI levels indicate overbought conditions.
VLO's outlook is positive due to refining margin strength and earnings beats, but risks include volatile energy prices and potential policy impacts like diesel export bans. The stock offers growth potential with a reasonable P/E of 18.51, yet high valuation multiples and technical overbought signals warrant caution for near-term entries.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
